NYSE
1.26USD
-0.01 (-0.79%)
We have scored 11 news catalysts on ADC Therapeutics S.A. (ADCT) over the past 12 months. The biggest single-day move next to one of them came Jun 4, 2026, when ADCT closed −57.1%: “ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data”. Coverage across the window leans negative (average ticker sentiment −0.29). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
160.3M
P/E
—
EPS
—
Beta
1.85
52W range
0.7796-4.98
Day range
1.20–1.27
Open
1.24
Prev close
1.27
Volume
833.6K
Avg volume
1.8M
Dividend
0.00
IPO
2020-05-18
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about ADC Therapeutics S.A. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ADCT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
